Cardiovascular Morbidity and Mortality Is Higher in Patients with Thyroid Hormone Resistance β Syndrome than in the General Population

Clinical Thyroidology®Vol. 35, No. 10 Thyroid Hormone ActionCardiovascular Morbidity and Mortality Is Higher in Patients with Thyroid Hormone Resistance β Syndrome than in the General PopulationElias Chuki, Amr Dorgham, and Joanna Klubo-GwiezdzinskaElias ChukiMetabolic Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland, U.S.A.Search for more papers by this author, Amr DorghamMetabolic Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland, U.S.A.Search for more papers by this author, and Joanna Klubo-GwiezdzinskaMetabolic Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland, U.S.A.Search for more papers by this authorPublished Online:5 Oct 2023https://doi.org/10.1089/ct.2023;35.398-401AboutSectionsView articleView Full TextPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View articleFiguresReferencesRelatedDetails Volume 35Issue 10Oct 2023 Information© Copyright 2023, Mary Ann Liebert, Inc.To cite this article:Elias Chuki, Amr Dorgham, and Joanna Klubo-Gwiezdzinska.Cardiovascular Morbidity and Mortality Is Higher in Patients with Thyroid Hormone Resistance β Syndrome than in the General Population.Clinical Thyroidology®.Oct 2023.398-401.http://doi.org/10.1089/ct.2023;35.398-401Published in Volume: 35 Issue 10: October 5, 2023PDF download